文献速递临床试验与 GCP

出院后托拉塞米与呋塞米对心力衰竭住院患者全因死亡率的影响:TRANSFORM-HF随机临床试验

Effect of Torsemide vs Furosemide After Discharge on All-Cause Mortality in Patients Hospitalized With Heart Failure: The TRANSFORM-HF Randomized Clinical Trial.
PubMed 文献 · JAMA · 2023-01-01

TRANSFORM-HF是一项开放标签、实用性随机试验,在美国60家医院招募2859例心力衰竭住院患者,比较托拉塞米(n=1431)与呋塞米(n=1428)对全因死亡率的影响。中位随访17.4个月,托拉塞米组死亡373例(26.1%),呋塞米组死亡374例(26.2%),风险比1.02(95%CI 0.89-1.18),两组无显著差异。作者结论认为出院后托拉塞米与呋塞米相比未显著降低全因死亡率,但结果解读受失访、交叉换药和不依从限制。

要点

  • 心力衰竭住院患者出院后使用托拉塞米与呋塞米相比,全因死亡率无显著差异(HR 1.02,95%CI 0.89-1.18)。
  • 12个月内全因死亡或全因住院:托拉塞米组47.3% vs 呋塞米组49.3%(HR 0.92,95%CI 0.83-1.02),未达统计学显著。
  • 结果在包括射血分数降低、轻度降低或保留的预设亚组中相似。

核心结论

  • 在心力衰竭住院后出院的患者中,与呋塞米相比,托拉塞米在12个月内未导致全因死亡率的显著差异。
  • 作者指出,这些发现的解读受到失访、参与者交叉换药和不依从的限制。

研究设计与样本

  • TRANSFORM-HF为开放标签、实用性随机试验,在美国60家医院招募2859例心力衰竭住院患者(无论射血分数)。
  • 招募时间为2018年6月至2022年3月,随访至30个月评估死亡、12个月评估住院,最终随访数据收集日期为2022年7月。
  • 干预为托拉塞米(n=1431)或呋塞米(n=1428)的袢利尿剂策略,剂量由研究者选择。
  • 主要结局为时间-事件分析中的全因死亡率;预设主要假设为托拉塞米较呋塞米降低全因死亡率20%。

主要发现

  • 中位随访17.4个月,共113例患者(托拉塞米组53例[3.7%],呋塞米组60例[4.2%])在完成前退出知情同意。
  • 托拉塞米组1431例中死亡373例(26.1%),呋塞米组1428例中死亡374例(26.2%)(HR 1.02,95%CI 0.89-1.18)。
  • 随机化后12个月内,托拉塞米组677例(47.3%) vs 呋塞米组704例(49.3%)发生全因死亡或全因住院(HR 0.92,95%CI 0.83-1.02)。
  • 托拉塞米组536例参与者共940次总住院,呋塞米组577例参与者共987次总住院(率比0.94,95%CI 0.84-1.07)。
  • 结果在包括射血分数降低、轻度降低或保留的预设亚组中相似。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文指出解读受失访、参与者交叉换药和不依从的限制。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Although furosemide is the most commonly used loop diuretic in patients with heart failure, some studies suggest a potential benefit for torsemide. OBJECTIVE: To determine whether torsemide results in decreased mortality compared with furosemide among patients hospitalized for heart failure. DESIGN, SETTING, AND PARTICIPANTS: TRANSFORM-HF was an open-label, pragmatic randomized trial that recruited 2859 participants hospitalized with heart failure (regardless of ejection fraction) at 60 hospitals in the United States. Recruitment occurred from June 2018 through March 2022, with follow-up through 30 months for death and 12 months for hospitalizations. The final date for follow-up data collection was July 2022. INTERVENTIONS: Loop diuretic strategy of torsemide (n = 1431) or furosemide (n = 1428) with investigator-selected dosage. MAIN OUTCOMES AND MEASURES: The primary outcome was all-cause mortality in a time-to-event analysis. There were 5 secondary outcomes with all-cause mortality or all-cause hospitalization and total hospitalizations assessed over 12 months being highest in the hierarchy. The prespecified primary hypothesis was that torsemide would reduce all-cause mortality by 20% compared with furosemide. RESULTS: TRANSFORM-HF randomized 2859 participants with a median age of 65 years (IQR, 56-75), 36.9% were women, and 33.9% were Black. Over a median follow-up of 17.4 months, a total of 113 patients (53 [3.7%] in the torsemide group and 60 [4.2%] in the furosemide group) withdrew consent from the trial prior to completion. Death occurred in 373 of 1431 patients (26.1%) in the torsemide group and 374 of 1428 patients (26.2%) in the furosemide group (hazard ratio, 1.02 [95% CI, 0.89-1.18]). Over 12 months following randomization, all-cause mortality or all-cause hospitalization occurred in 677 patients (47.3%) in the torsemide group and 704 patients (49.3%) in the furosemide group (hazard ratio, 0.92 [95% CI, 0.83-1.02]). There were 940 total hospitalizations among 536 participants in the torsemide group and 987 total hospitalizations among 577 participants in the furosemide group (rate ratio, 0.94 [95% CI, 0.84-1.07]). Results were similar across prespecified subgroups, including among patients with reduced, mildly reduced, or preserved ejection fraction. CONCLUSIONS AND RELEVANCE: Among patients discharged after hospitalization for heart failure, torsemide compared with furosemide did not result in a significant difference in all-cause mortality over 12 months. However, interpretation of these findings is limited by loss to follow-up and participant crossover and nonadherence. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT03296813.

来源:JAMA,查看原文。版权归原作者所有。

引用

  1. Mentz RJ, Anstrom KJ, Eisenstein EL, et al. Effect of Torsemide vs Furosemide After Discharge on All-Cause Mortality in Patients Hospitalized With Heart Failure: The TRANSFORM-HF Randomized Clinical Trial. JAMA. 2023. PMID: 36648467. doi:10.1001/jama.2022.23924

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。